– USA, PA – BioTelemetry, Inc. (NASDAQ:BEAT) announced today that Stephan Rietiker has been elected to BioTelemetry’s Board of Directors.
Dr. Rietiker was most recently the Chief Executive Officer of LifeWatch AG, until it was acquired by BioTelemetry in August 2017. Prior to becoming CEO of LifeWatch AG in 2014, Dr. Rietiker held executive roles at Roche, Boehringer Mannheim, Schering Plough, Covance and as CEO of Centerpulse. Additionally, he has been an investor, executive and Board Member of several developmental-stage companies and has been a Senior Advisor to Brown Brothers Harriman’s M&A practice.
Dr. Rietiker, a Swiss-US dual citizen, is a trained physician with a doctorate from the University of Zurich, Switzerland, and is also qualified to practice medicine in the United States.
Joseph Capper, President and Chief Executive Officer of BioTelemetry commented, “We are extremely pleased and honored to welcome Steve to the Board of Directors. His active participation was vital to the highly successful merger and integration of LifeWatch into BioTelemetry. Steve’s proven leadership, in-depth understanding of the healthcare industry and experience in global markets make him an ideal addition to our Board.”
About BioTelemetry
BioTelemetry, Inc. is the leading remote and wireless medical technology company focused on delivery of health information to improve quality of life and reduce cost of care. We provide cardiac monitoring, mobile blood glucose monitoring, centralized medical imaging, and original equipment manufacturing that serves both the Healthcare and Clinical Research industries.
For more information : https://www.gobio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
